Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKR1C3 | P42330 | 1/20 | 0.42 |
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.42 |
| ▸ | SLC18A3 | Q16572 | 7/20 | 0.39 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.37 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.36 |
| ▸ | HTR2C | P28335 | 1/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.36 |
| ▸ | KCNA5 | P22460 | 1/20 | 0.35 |
| ▸ | SLC5A1 | P13866 | 1/20 | 0.35 |
| ▸ | SLC5A2 | P31639 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15906232 | 0.79 | AKR1C3 (0.46) | AKR1C3AKR1C1SLC18A3SIGMAR1CYP3A4 | |
| SCHEMBL30969350 | 0.76 | AKR1C3 (0.46) | AKR1C3AKR1C1SLC18A3SIGMAR1 | |
| SCHEMBL18584919 | 0.76 | AKR1C3 (0.46) | AKR1C3AKR1C1SLC18A3SIGMAR1CYP3A4 | |
| SCHEMBL2030780 | 0.76 | AKR1C3 (0.50) | AKR1C3AKR1C1SLC18A3SIGMAR1HTR2C | |
| SCHEMBL13718761 | 0.75 | SLC18A3 (0.45) | AKR1C3AKR1C1SLC18A3SIGMAR1HTR2C | |
| SCHEMBL14310592 | 0.75 | AKR1C3 (0.42) | AKR1C3AKR1C1SLC18A3SIGMAR1HTR2C | |
| Hydrochloric Acid SCHEMBL81099 | 0.74 | AKR1C3 (0.49) | AKR1C3AKR1C1SLC18A3SIGMAR1HTR2C | |
| SCHEMBL8029809 | 0.71 | SLC18A3 (0.56) | AKR1C3AKR1C1SLC18A3SIGMAR1CYP3A4 | |
| SCHEMBL26999319 | 0.71 | SLC18A3 (0.56) | AKR1C3AKR1C1SLC18A3SIGMAR1CYP3A4 | |
| SCHEMBL8029813 | 0.71 | SLC18A3 (0.56) | AKR1C3AKR1C1SLC18A3SIGMAR1CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8791257-B2 | Substituted pyrrolotriazines as protein kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2014-07-29 | — | — | US | disclosed |
| US-20130023514-A1 | SUBSTITUTED PYRROLOTRIAZINES AS PROTEIN KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-01-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130023514-A1 | SUBSTITUTED PYRROLOTRIAZINES AS PROTEIN KINASE INHIBITORS | STK25, MAP3K15, MAP3K5 | AKR1C3 3523/4885AKR1C1 2689/4885SLC18A3 4714/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.